Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endocrine changes in Alzheimer's disease.

M Davidson1, L Bastiaens, B M Davis

  • 1Bronx Veterans Administration Medical Center, New York.

Endocrinology and Metabolism Clinics of North America
|March 1, 1988
PubMed
Summary

Current research indicates no consistent endocrine abnormalities in Alzheimer's disease patients. However, neuroendocrine function tests may reveal specific neurotransmission issues, guiding personalized pharmacologic strategies for improved outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Research and development of a silicone letrozole-releasing device to control reproduction in cattle.

Theriogenology·2020
Same author

Corrigendum to "Topical Coenzyme Q10 demonstrates mitochondrial-mediated neuroprotection in a rodent model of ocular hypertension" [Mitochondrion 36 (2017) 114-123].

Mitochondrion·2019
Same author

Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma.

Journal of controlled release : official journal of the Controlled Release Society·2019
Same author

Automatic quantitative analysis of experimental primary and secondary retinal neurodegeneration: implications for optic neuropathies.

Cell death discovery·2016
Same author

Towards maximising information extraction from rodent models of ocular disease.

Cell death & disease·2016
Same author

TRAF family member-associated NF-kappa B activator (TANK) expression increases in injured sensory neurons and is transcriptionally regulated by Sox11.

Neuroscience·2012

Area of Science:

  • Neuroendocrinology
  • Alzheimer's Disease Pathophysiology

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
  • Endocrine and neuroendocrine functions are often implicated in neurological conditions.

Purpose of the Study:

  • To investigate potential endocrine abnormalities in Alzheimer's disease.
  • To explore the utility of neuroendocrine function assessment in identifying patient subpopulations for targeted pharmacologic interventions.

Main Methods:

  • The study involved assessing neuroendocrine function in Alzheimer's disease patients.
  • Correlations between endocrine responses and symptomatic benefits of pharmacologic treatments were examined.

Main Results:

  • No consistent endocrine abnormalities were detected in the general Alzheimer's disease patient cohort.

Related Experiment Videos

  • A subset of patients demonstrated specific neurotransmission abnormalities identifiable through neuroendocrine assessment.

    • Conclusions:

    • While no universal endocrine dysfunction is evident in Alzheimer's disease, neuroendocrine assessment can identify specific patient groups.
    • Identifying these subpopulations may enable tailored pharmacologic strategies, such as using cholinomimetic drugs based on cortisol response, to improve symptomatic relief.